
HER2-low breast cancer benefits from targeted therapy! The DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan effectively treats tumors without HER2 overexpression. However, semiquantitative IHC assays lack precision in detecting low HER2 levels, making the exclusion of IHC 0 patients from the trial questionable. The ASCO-CAP panel recognizes the need for clearer IHC 1+ vs. IHC 0 distinctions to refine treatment eligibility and improve patient outcomes.
Like
Save
Share